Arena Pharmaceuticals, Inc.
6154 Nancy Ridge Drive
San Diego
CA
92121
United States
Tel: 858-453-7200
Fax: 858-453-7210
Website: http://www.arenapharm.com/
Email: invest@arenapharm.com
149 articles about Arena Pharmaceuticals, Inc.
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 18, 2021
2/18/2021
Arena Pharmaceuticals, Inc. announced that on February 15, 2021, the Compensation Committee of its Board of Directors granted to eleven new employees inducement stock options to purchase an aggregate of 33,885 shares of its common stock and 8,475 inducement restricted stock units.
-
Arena Pharmaceuticals Announces Changes to Board of Directors
2/16/2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to the Company’s Board of Directors. Garry Neil, MD, has been appointed Chair of the Board. Additionally, Nawal Ouzren has been appointed as a new Board member.
-
Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23
2/16/2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2020 financial results and provide a corporate update on Tuesday, February 23, 2021, after the close of the U.S. financial markets.
-
Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial
2/2/2021
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has completed full enrollment of the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderately-to-severely active ulcerative colitis
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 22, 2021
1/22/2021
Arena Pharmaceuticals, Inc. announced that on January 15, 2021, the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 16,950 shares of its common stock and 3,470 inducement restricted stock units.
-
Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13
12/22/2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 , at 10:00 AM ET . A live webcast of the presentation will be posted under t
-
Arena Pharmaceuticals Reported Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/18/2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 141,975 shares of its common stock and 2,460 inducement restricted stock units ("RSUs"). The inducement stock o
-
Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference
12/11/2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that data from the Phase 2b ADVISE trial evaluating the safety and efficacy of etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderate-to-severe atopic dermatitis (AD), will be presented at the Revolutionizing Atopic Dermatitis (RAD) 2020 Virtual Conference.
-
Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial
12/8/2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that it has achieved its targeted enrollment goal of 372 participants in the Phase 3 ELEVATE UC 52 trial evaluating the safety and efficacy of once-daily etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, in participants with moderately-to-severely active ulcerative colitis.
-
Although biopharma executives leave for many reasons and at any time, there is a tendency to make shifts toward the end of the year. Today there were two high-profile announcements to start off the month of December.
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 19, 2020
11/19/2020
Arena Pharmaceuticals, Inc. announced that on November 15, 2020, the Compensation Committee of its Board of Directors granted to 13 new employees inducement stock options to purchase an aggregate of 96,025 shares of its common stock and 17,590 inducement restricted stock units.
-
Arena Reports Third Quarter Financial Results with Strong Cash Position, Advancing Etrasimod Into a Phase 3 Registrational Program in Atopic Dermatitis
11/9/2020
Delivered compelling topline results from ADVISE Ph 2b trial evaluating etrasimod in atopic dermatitis; advancing into a Ph 3 registrational program
-
Arena Pharmaceuticals Advancing Etrasimod Into Phase 3 Program in Atopic Dermatitis (AD), Reports Compelling Topline Results from Phase 2b ADVISE Trial
11/9/2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced topline results from the Phase 2b ADVISE clinical trial evaluating etrasimod, a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator, for the treatment of moderate-to-severe atopic dermatitis (AD).
-
Arena Pharmaceuticals to Release Third Quarter 2020 Financial Results and Provide Corporate Update on November 9
11/2/2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its third quarter 2020 financial results and provide a corporate update on Monday, November 9, 2020 , after the close of the U.S. financial markets. The Company will host a conference call and live webcast to discuss the results with the investment community the same day at 4:3
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 20, 2020
10/20/2020
Arena Pharmaceuticals, Inc. announced that on October 15, 2020, the Compensation Committee of its Board of Directors granted to seven new employees inducement stock options to purchase an aggregate of 66,475 shares of its common stock and 11,760 inducement restricted stock units.
-
Arena Pharmaceuticals' Presence at United European Gastroenterology Week Strengthens Ongoing Commitment to the Gastrointestinal Disease Community
10/9/2020
- New data from the Phase 2 OASIS trial and its open-label extension for etrasimod in ulcerative colitis - Arena sponsored symposium: Opening the Door to Emerging Investigational Treatments in Ulcerative Colitis: What Awaits Us? [09-October-2020] SAN DIEGO , Oct. 9, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will present new data from
-
Arena Pharmaceuticals Completes Full Enrollment of Olorinab Phase 2 CAPTIVATE Trial for Abdominal Pain in Irritable Bowel Syndrome
10/1/2020
- Evaluating 3 doses of olorinab in study participants with the clinical diagnosis of irritable bowel syndrome with predominant constipation (IBS-C) or diarrhea (IBS-D) - Topline data expected Q1 2021 - Significant unmet need for non-opioid, peripherally acting pain management in gastrointestinal disorders [01-October-2020] SAN DIEGO , Oct. 1, 2020
-
Arena Pharmaceuticals to Present at the Jefferies Virtual Next Generation IBD Therapeutics Summit
9/18/2020
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi, the Company's President and Chief Executive Officer, will present a corporate update at the Jefferies Virtual Next Generation IBD Therapeutics Summit on Wednesday, September 23, at 1:45 PM ET.
-
Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 18, 2020
9/18/2020
Arena Pharmaceuticals, Inc. announced that on September 15, 2020, the Compensation Committee of its Board of Directors granted to nine new employees inducement stock options to purchase an aggregate of 68,825 shares of its common stock and 12,420 inducement restricted stock units.
-
Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 12 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis
9/16/2020
- Evaluating etrasimod 2 mg in patients with the clinical diagnosis of moderately to severely active ulcerative colitis (UC) - Significant unmet need for new effective oral therapies in UC [16-September-2020] SAN DIEGO , Sept. 16, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the first subject has been dosed in the EL